Department of Public Expenditure, Infrastructure, Public Service Reform and Digitalisation

Please provide all meeting minutes and all correspondence, between September 2023 and now, about the funding and reimbursement of new drugs, between your department and the following pharmaceutical groups and interests groups: Johnson & Johnson / Janssen, Merck / MSD, Novartis, Pfizer, Sanofi, Astra Zeneca, Bristol Myers Squibb, Abbvie / Abbott Laboratories, Bayer, Roche, Glaxo Smith Kline, Eli Lilly, Novo Nordisk, Amgen, Gilead, Vertex Pharmaceuticals, the Irish Pharmaceutical Healthcare Association. Please also provide any briefing, note, presentation or any document shared or created in preparation or as a result of these meetings and correspondence.